MiR-375/SLC7A11 axis regulates oral squamous cell carcinoma proliferation and invasion

Cancer Medicine

Volumn 6, Issue 7, 2017, Pages 1686-1697

  Wu, Yadong ^a,b   Sun, Xiangjie ^c,d   Song, Bin ^b   Qiu, Xiaoling ^a   Zhao, Jianjiang ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUIZHOU PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

miR 375; OSCC; SLC7A11

Indexed keywords

MEMBRANE PROTEIN; MICRORNA 375; SOLUTE CARRIER FAMILY 7 MEMBER 11; UNCLASSIFIED DRUG; AMINO ACID TRANSPORTER; MICRORNA; MIRN375 MICRORNA, HUMAN; SLC7A11 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CELL COUNT; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; SQUAMOUS CELL CARCINOMA CELL; UPREGULATION; CELL MOTION; CELL SURVIVAL; GENETICS; MITOSIS; MOUTH TUMOR; PATHOLOGY; RNA INTERFERENCE; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; AMINO ACID TRANSPORT SYSTEM Y+; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MITOSIS; MOUTH NEOPLASMS; RNA INTERFERENCE;

EID: 85020509517     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.1110     Document Type: Article

References (40)

1. Shi, W., J. Yang, S. Li, X. Shan, X. Liu, H. Hua, et al. 2015. Potential involvement of miR-375 in the premalignant progression of oral squamous cell carcinoma mediated via transcription factor KLF5. Oncotarget 6:40172–40185.
2. Choi, S., and J. N. Myers. 2008. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J. Dent. Res. 87:14–32.
3. Zini, A., R. Czerninski, and H. D. Sgan-Cohen. 2010. Oral cancer over four decades: epidemiology, trends, histology, and survival by anatomical sites. J. Oral Pathol. Med. 39:299–305.
4. Forastiere, A., W. Koch, A. Trotti, and D. Sidransky. 2001. Head and neck cancer. N. Engl. J. Med. 345:1890–1900.
5. Haddad, R. I., and D. M. Shin. 2008. Recent advances in head and neck cancer. N. Engl. J. Med. 359:1143–1154.
6. Bartels, C. L., and G. J. Tsongalis. 2009. MicroRNAs: novel biomarkers for human cancer. Clin. Chem. 55:623–631.
7. Lujambio, A., and S. W. Lowe. 2012. The microcosmos of cancer. Nature 482:347–355.
8. Ambros, V., and X. Chen. 2007. The regulation of genes and genomes by small RNAs. Development 134:1635–1641.
9. Inui, M., G. Martello, and S. Piccolo. 2010. MicroRNA control of signal transduction. Nat. Rev. Mol. Cell Biol. 11:252–263.
10. Shin, K. H., S. D. Bae, H. S. Hong, R. H. Kim, M. K. Kang, and N. H. Park. 2011. miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras. Biochem. Biophys. Res. Comm. 404:896–902.
11. Sun, D., X. Li, M. Ma, J. Liu, Y. Xu, L. Ye, et al. 2015. The predictive value and potential mechanisms of miRNA-328 and miRNA-378 for brain metastases in operable and advanced non-small-cell lung cancer. Jpn. J. Clin. Oncol. 45:464–473.
12. Kozaki, K., I. Imoto, S. Mogi, K. Omura, and J. Inazawa. 2008. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Can. Res. 68:2094–2105.
13. Iorio, M. V., M. Ferracin, C. G. Liu, A. Veronese, R. Spizzo, S. Sabbioni, et al. 2005. MicroRNA gene expression deregulation in human breast cancer. Can. Res. 65:7065–7070.
14. Yan, L. X., X. F. Huang, Q. Shao, M. Y. Huang, L. Deng, Q. L. Wu, et al. 2008. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 14:2348–2360.
15. Yoshino, H., T. Chiyomaru, H. Enokida, K. Kawakami, S. Tatarano, K. Nishiyama, et al. 2011. The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br. J. Cancer 104:808–818.
16. Abraham, D., N. Jackson, J. S. Gundara, J. Zhao, A. J. Gill, L. Delbridge, et al. 2011. MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets. Clin. Cancer Res. 17:4772–4781.
17. Basu, A., H. Alder, A. Khiyami, P. Leahy, C. M. Croce, and S. Haldar. 2011. MicroRNA-375 and microRNA-221: potential noncoding RNAs associated with antiproliferative activity of benzyl isothiocyanate in pancreatic cancer. Genes Cancer 2:108–119.
18. Yoon, A. J., S. Wang, J. Shen, N. Robine, E. Philipone, M. W. Oster, et al. 2014. Prognostic value of miR-375 and miR-214-3p in early stage oral squamous cell carcinoma. Am. J. Transl. Res. 6:580–592.
19. Okuno, S., H. Sato, K. Kuriyama-Matsumura, M. Tamba, H. Wang, S. Sohda, et al. 2003. Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. Br. J. Cancer 88:951–956.
20. Sato, H., M. Tamba, T. Ishii, and S. Bannai. 1999. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J. Biol. Chem. 274:11455–11458.
21. Lu, S. C. 2013. Glutathione synthesis. Biochem. Biophys. Acta. 1830:3143–3153.
22. Wada, T., T. Ishimoto, R. Seishima, K. Tsuchihashi, M. Yoshikawa, H. Oshima, et al. 2013. Functional role of CD44v-xCT system in the development of spasmolytic polypeptide-expressing metaplasia. Cancer Sci. 104:1323–1329.
23. Drayton, R. M., E. Dudziec, S. Peter, S. Bertz, A. Hartmann, H. E. Bryant, et al. 2014. Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin. Cancer Res. 20:1990–2000.
24. Liu, X. X., X. J. Li, B. Zhang, Y. J. Liang, C. X. Zhou, D. X. Cao, et al. 2011. MicroRNA-26B is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11. FEBS Lett. 585:1363–1367.
25. Takeuchi, S., K. Wada, T. Toyooka, N. Shinomiya, H. Shimazaki, K. Nakanishi, et al. 2013. Increased xct expression correlates with tumor invasion and outcome in patients with glioblastomas. Neurosurgery 72:33–41; discussion 41.
26. Huang, Y., Z. Dai, C. Barbacioru, and W. Sadee. 2005. Cystine-glutamate transporter slc7a11 in cancer chemosensitivity and chemoresistance. Can. Res. 65:7446–7454.
27. Savaskan, N. E., A. Heckel, E. Hahnen, T. Engelhorn, A. Doerfler, O. Ganslandt, et al. 2008. Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat. Med. 14:629–632.
28. Zhang, P., W. Wang, Z. Wei, L. I. Xu, X. Yang, and Y. Du. 2016. xCT expression modulates cisplatin resistance in Tca8113 tongue carcinoma cells. Oncol. Lett. 12:307–314.
29. Eid, A., S. Li, R. Garza, and M. E. Wong. 2014. Chemotherapy for oral and maxillofacial tumors: an update. Oral Maxillofac. Surg. Clin. N. Am. 26:163–169.
30. Chen, D., W. Yan, Z. Liu, Z. Zhang, L. Zhu, W. Liu, et al. 2016. Downregulation of miR-221 enhances the sensitivity of human oral squamous cell carcinoma cells to Adriamycin through upregulation of TIMp3 expression. Biomed. Pharmacother. 77:72–78.
31. Mao, Q., T. Quan, B. Luo, X. Guo, L. Liu, and Q. Zheng. 2016. MiR-375 targets KLF4 and impacts the proliferation of colorectal carcinoma. Tumour Biol. 37:463–471.
32. Lamperska, K. M., P. Kozlowski, T. Kolenda, A. Teresiak, R. Blizniak, W. Przybyla, et al. 2016. Unpredictable changes of selected miRNA in expression profile of HNSCC. Cancer Biomark. 16:55–64.
33. Koppers-Lalic, D., M. Hackenberg, R. de Menezes, B. Misovic, M. Wachalska, A. Geldof, et al. 2016. Noninvasive prostate cancer detection by measuring miRNA variants (isomiRS) in urine extracellular vesicles. Oncotarget 7:22566–22578.
34. Kim, H. S., K. S. Lee, H. J. Bae, J. W. Eun, Q. Shen, S. J. Park, et al. 2015. MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer. Oncotarget 6:8089–8102.
35. Keklikoglou, I., C. Koerner, C. Schmidt, J. D. Zhang, D. Heckmann, A. Shavinskaya, et al. 2012. MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kappaB and TGF-beta signaling pathways. Oncogene 31:4150–4163.
36. deSteenweg- Graaff, J. C., H. Tiemeier, M. G. Basten, J. Rijlaarsdam, H. Demmelmair, B. Koletzko, et al. 2015. Maternal LC-PUFA status during pregnancy and child problem behavior: the generation R study. Pediatr. Res. 77: 489–497.
37. Siow, M. Y., L. P. Ng, V. K. Vincent-Chong, M. Jamaludin, M. T. Abraham, Z. A. Abdul Rahman, et al. 2014. Dysregulation of miR-31 and miR-375 expression is associated with clinical outcomes in oral carcinoma. Oral Dis. 20:345–351.
38. Jia, L., Y. Huang, Y. Zheng, M. Lyu, C. Zhang, Z. Meng, et al. 2015. miR-375 inhibits cell growth and correlates with clinical outcomes in tongue squamous cell carcinoma. Oncol. Rep. 33:2061–2071.
39. Qin, Z., E. Freitas, R. Sullivan, S. Mohan, R. Bacelieri, D. Branch, et al. 2010. Upregulation of xCT by KSHV-encoded microRNAs facilitates KSHV dissemination and persistence in an environment of oxidative stress. PLoS Pathog. 6:e1000742.
40. Toyoda, M., K. Kaira, Y. Ohshima, N. S. Ishioka, M. Shino, K. Sakakura, et al. 2014. Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer. Br. J. Cancer 110:2506–2513.